Back to Search Start Over

Asprosin, a Fasting-Induced Glucogenic Protein Hormone.

Authors :
Romere, Chase
Romere, Chase
Duerrschmid, Clemens
Bournat, Juan
Constable, Petra
Jain, Mahim
Xia, Fan
Saha, Pradip K
Del Solar, Maria
Zhu, Bokai
York, Brian
Sarkar, Poonam
Rendon, David A
Gaber, M Waleed
LeMaire, Scott A
Coselli, Joseph S
Milewicz, Dianna M
Sutton, V Reid
Butte, Nancy F
Moore, David D
Chopra, Atul R
Romere, Chase
Romere, Chase
Duerrschmid, Clemens
Bournat, Juan
Constable, Petra
Jain, Mahim
Xia, Fan
Saha, Pradip K
Del Solar, Maria
Zhu, Bokai
York, Brian
Sarkar, Poonam
Rendon, David A
Gaber, M Waleed
LeMaire, Scott A
Coselli, Joseph S
Milewicz, Dianna M
Sutton, V Reid
Butte, Nancy F
Moore, David D
Chopra, Atul R
Source :
Cell; vol 165, iss 3, 566-579; 0092-8674
Publication Year :
2016

Abstract

Hepatic glucose release into the circulation is vital for brain function and survival during periods of fasting and is modulated by an array of hormones that precisely regulate plasma glucose levels. We have identified a fasting-induced protein hormone that modulates hepatic glucose release. It is the C-terminal cleavage product of profibrillin, and we name it Asprosin. Asprosin is secreted by white adipose, circulates at nanomolar levels, and is recruited to the liver, where it activates the G protein-cAMP-PKA pathway, resulting in rapid glucose release into the circulation. Humans and mice with insulin resistance show pathologically elevated plasma asprosin, and its loss of function via immunologic or genetic means has a profound glucose- and insulin-lowering effect secondary to reduced hepatic glucose release. Asprosin represents a glucogenic protein hormone, and therapeutically targeting it may be beneficial in type II diabetes and metabolic syndrome.

Details

Database :
OAIster
Journal :
Cell; vol 165, iss 3, 566-579; 0092-8674
Notes :
application/pdf, Cell vol 165, iss 3, 566-579 0092-8674
Publication Type :
Electronic Resource
Accession number :
edsoai.on1391595493
Document Type :
Electronic Resource